secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0000950170-24-107031
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira cuts 70% of workforce, pivots to ATH-1105 after LIFT-AD readout
----------------------------------------------------------------------

- Workforce reduction of ~70% (49 positions); one-time costs ~$2.8M third-quarter 2024.
- Annualized cost savings ~$13.4M; cash runway extended into Q1 2026.
- CFO Andrew Gengos and COO Rachel Lenington terminated without cause, effective Oct 1, 2024.
- VP Finance Robert Renninger appointed principal financial and accounting officer.
- Focus shifts to ATH-1105 (oral HGF modulator) for ALS; Phase 1 completes by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024107031/0000950170-24-107031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024107031/atha-20240915.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer